Abstract: |
Monoclonal antibodies which recognize human tumor antigens have been used to target radioactivity to tumor sites. Radiolabeled antibodies are injected parenterally, and pass through the blood and capillary membranes to diffuse throughout the body tissues. When tumor associated antigen is encountered, the antibody binds, and over time, there is a progressive accumulation of radioactivity at the tumor site. Antibody which is not bound to tumor is gradually cleared from normal tissue regions, and a gradient develops between the tumor and the normal tissues of the host. A fundamental goal of this targeting approach is to achieve the maximum gradient between tumor and normal tissues. Large scale clinical trials have demonstrated that for common tumors, including colorectal carcinoma and ovarian cancer, that occult tumor can be detected with radioimmunodetection when other diagnostic methods such as TCT are negative. Recent technical advances are likely to lead to improvements in radioimmunodetection and include Tc-99m labeling of monoclonal antibodies; increased resolution and sensitivity of single photon emission tomography methods; improved correlation of transmission computerized tomography and radiolabeled antibody studies (FUSION imaging); the beginnings of quantitative imaging methods with positron emission tomography; and positron emitting radiolabeled antibodies. |